JustinCMoserMD

Melanoma

Associate Clinical Investigator, HonorHealth Research and Innovation Institute Clinical Assistant Professor, University of Arizona College of Medicine - Phoenix Adjunct Faculty, Translational Genomic Research Institute (TGen)

Join to view full profile

Dr. Moser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moser's full profile

Already have an account?

Office
10510 N 92nd St
Ste 200
Scottsdale, AZ 85258
Phone+1 480-323-4638

Summary

Melanoma and Phase 1 specialist, with special focus on immunotherapeutics and uveal melanoma

Education & Training

University of Utah HealthFellowship, Hematology and Medical Oncology, 2016 - 2019
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2013 - 2016
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2013

Certifications & Licensure

AZ State Medical License 2019 - 2026
UT State Medical License 2016 - 2020
MN State Medical License 2014 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Innovation Award The Arizona Clinical Oncology Society, 2021
Visiting Fellow, Cancer Therapy Evaluation Program National Cancer Institute, 2017
National ACP Doctors Dilemma Semi-Finalist Team Member 2016
Young Achiver Award Recipient National ACP Conference, 2016
Join now to see all

Publications & Presentations

PubMed

Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2024-10-23
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab ...
Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, Justin Moser, Michael Millward
Journal for Immunotherapy of Cancer. 2024-08-03
DNA mismatch repair deficiency in conjunctival melanoma.
Aurora Rodriguez, Justin Moser, Aparna Ramasubramanian
Eye. 2024-08-01

Press Mentions

New HonorHealth Treatment Aims to Eliminate Melanoma with a Single BlowMay 2nd, 2024
‘COVID Saved My Life:’ Phoenix Mom Says Virus Helped Reveal Cancerous TumorsAugust 8th, 2024

Grant Support

Travel Grant Award RecipientDepartment of Experiemental Therapuetics, Huntsman Cancer Institute2017–Present
Medical Oncology Small GrantMayo Clinic2015–Present